| 2022-03-08 |
详情>>
股本变动：
变动后总股本7719.86万股
|
| 2022-03-08 |
详情>>
业绩披露：
2021年年报每股收益-0.78美元,归母净利润-5923.7万美元,同比去年增长-11.73%
|
| 2022-02-24 |
股东大会：
将于2022-03-25召开股东大会
会议内容 ▼▲
- 1.To consider and vote upon a proposal, which we refer to as the “Charter Amendment Proposal,” to amend the Company’s Eighth Amended and Restated Certificate of Incorporation (the “Charter”), a form of which amendment is attached as Annex A to the accompanying proxy statement, to, among other things, (1) increase the number of shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) that the Company is authorized to issue from two hundred million (200,000,000) shares to four hundred million (400,000,000) shares and (2) change the name of the Company to Standard BioTools Inc.
2.To consider and vote upon a proposal, which we refer to as the “Private Placement Issuance Proposal,” to approve, in accordance with Nasdaq Listing Rule 5635, the issuance of (1) the Series B-1 Convertible Preferred Stock, par value $0.001 per share, of the Company (the “Series B-1 Preferred Stock”) and the Series B-2 Convertible Preferred Stock, par value $0.001 per share, of the Company (the “Series B-2 Preferred Stock”, and together with the Series B-1 Preferred Stock, the “Series B Preferred Stock”) issuable pursuant to the Purchase Agreements, (2) the Series B-1 Preferred Stock and the Series B-2 Preferred Stock issuable pursuant to the terms of the Loan Agreements and (3) the Common Stock issuable upon the conversion of the Series B Preferred Stock.
3.To consider and vote upon a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve the Charter Amendment Proposal and the Private Placement Issuance Proposal at the time of the Special Meeting, which we refer to as the “Adjournment Proposal.”
|
| 2022-02-24 |
股东大会：
将于2022-04-01召开股东大会
会议内容 ▼▲
- 1.To consider and vote upon a proposal, which we refer to as the “Charter Amendment Proposal,” to amend the Company’s Eighth Amended and Restated Certificate of Incorporation (the “Charter”), a form of which amendment is attached as Annex A to the accompanying proxy statement, to, among other things, (1) increase the number of shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) that the Company is authorized to issue from two hundred million (200,000,000) shares to four hundred million (400,000,000) shares and (2) change the name of the Company to Standard BioTools Inc.
2.To consider and vote upon a proposal, which we refer to as the “Private Placement Issuance Proposal,” to approve, in accordance with Nasdaq Listing Rule 5635, the issuance of (1) the Series B-1 Convertible Preferred Stock, par value $0.001 per share, of the Company (the “Series B-1 Preferred Stock”) and the Series B-2 Convertible Preferred Stock, par value $0.001 per share, of the Company (the “Series B-2 Preferred Stock”, and together with the Series B-1 Preferred Stock, the “Series B Preferred Stock”) issuable pursuant to the Purchase Agreements, (2) the Series B-1 Preferred Stock and the Series B-2 Preferred Stock issuable pursuant to the terms of the Loan Agreements and (3) the Common Stock issuable upon the conversion of the Series B Preferred Stock.
3.To consider and vote upon a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve the Charter Amendment Proposal and the Private Placement Issuance Proposal at the time of the Special Meeting, which we refer to as the “Adjournment Proposal.”
|
| 2021-11-09 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.66美元,归母净利润-4980.8万美元,同比去年增长-42.33%
|
| 2021-11-08 |
财报披露：
美东时间 2021-11-08 盘后发布财报
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-06 |
详情>>
业绩披露：
2021年中报每股收益-0.48美元,归母净利润-3596.4万美元,同比去年增长-24.04%
|
| 2021-05-07 |
详情>>
业绩披露：
2021年一季报每股收益-0.25美元,归母净利润-1882.1万美元,同比去年增长-17.78%
|
| 2021-04-14 |
股东大会：
将于2021-05-25召开股东大会
会议内容 ▼▲
- 1.To elect the three nominees for Class II director named in this proxy statement, each to hold office until our 2024 annual meeting of stockholders or until his or her successor is duly elected and qualified.
2.To vote, on an advisory basis, to approve the compensation of our named executive officers for the year ended December 31, 2020, as set forth in this proxy statement.
3.To vote on an amendment of our 2011 Equity Incentive Plan to increase the shares reserved thereunder and to make certain other changes.
4.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2021.
5.To transact any other business that may properly come before the 2021 Annual Meeting.
|
| 2021-02-25 |
详情>>
业绩披露：
2018年年报每股收益-1.49美元,归母净利润-5901.3万美元,同比去年增长2.51%
|
| 2021-02-25 |
详情>>
业绩披露：
2020年年报每股收益-0.74美元,归母净利润-5302万美元,同比去年增长18.17%
|
| 2020-11-09 |
详情>>
业绩披露：
2019年三季报(累计)每股收益-0.79美元,归母净利润-5210.5万美元,同比去年增长-17.78%
|
| 2020-11-09 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-0.49美元,归母净利润-3499.4万美元,同比去年增长32.84%
|
| 2020-08-07 |
详情>>
业绩披露：
2020年中报每股收益-0.41美元,归母净利润-2899.5万美元,同比去年增长26.07%
|
| 2020-05-14 |
股东大会：
将于2020-06-23召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees for Class I director named in this proxy statement, each to hold office until our 2023 annual meeting of stockholders or until his successor is duly elected and qualified.
2.To vote, on an advisory basis, to approve the compensation of our named executive officers for the year ended December 31, 2019, as set forth in this proxy statement.
3.To vote on an amendment and restatement of our 2017 Employee Stock Purchase Plan to increase the shares reserved thereunder and to make certain other changes.
4.To vote on an amendment to our 2011 Equity Incentive Plan to increase the shares reserved thereunder
5.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2020.
6.To transact any other business that may properly come before the 2020 Annual Meeting.
|
| 2020-05-11 |
详情>>
业绩披露：
2020年一季报每股收益-0.23美元,归母净利润-1598万美元,同比去年增长37.25%
|
| 2020-05-02 |
复牌提示：
2020-05-01 15:17:11 停牌，复牌日期 2020-05-01 15:22:11
|
| 2020-02-27 |
详情>>
业绩披露：
2019年年报每股收益-0.97美元,归母净利润-6479万美元,同比去年增长-9.79%
|
| 2019-04-23 |
股东大会：
将于2019-06-03召开股东大会
会议内容 ▼▲
- 1.To elect the three nominees for Class III director named in this proxy statement, each to hold office until our 2022 annual meeting of stockholders or until his or her successor is duly elected and qualified.
2.To vote, on an advisory basis, to approve the compensation of our named executive officers for the year ended December 31, 2018, as set forth in this proxy statement.
3.To vote on an amendment and restatement of our 2011 Equity Incentive Plan to increase the shares reserved thereunder and to make certain other changes.
4.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2019.
5.To transact any other business that may properly come before the 2019 Annual Meeting.
|
| 2018-08-20 |
详情>>
内部人交易：
Khadder Nicholas等共交易17笔
|
| 2018-04-27 |
股东大会：
将于2018-05-31召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees for Class II director named in this proxy statement, each to hold office until our 2021 annual meeting of stockholders or until his successor is duly elected and qualified.
2.To vote, on an advisory basis, to approve the compensation of our named executive officers for the year ended December 31, 2017, as set forth in this proxy statement.
3.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2018.
4.To transact any other business that may properly come before the 2018 annual meeting.
|
| 2017-06-29 |
股东大会：
将于2017-08-01召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees for Class I director named in this proxy statement, each to hold office until our 2020 annual meeting of stockholders or until his successor is duly elected and qualified.
2.To vote, on an advisory basis, to approve the compensation of our named executive officers for the year ended December 31, 2016, as set forth in this proxy statement.
3.To vote, on an advisory basis, on the frequency of a stockholder vote on executive compensation.
4.To approve the 2017 Employee Stock Purchase Plan.
5.To approve amendments to our equity compensation plans to allow for a one-time stock option exchange program.
6.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2017.
7.To transact any other business that may properly come before the 2017 annual meeting.
|
| 2016-06-30 |
股东大会：
将于2016-08-03召开股东大会
会议内容 ▼▲
- 1. To elect the two nominees for Class III director named in this proxy statement, each to hold office until our 2019 annual meeting of stockholders or until his successor is duly elected and qualified.
2. To vote, on an advisory basis, to approve the compensation of our named executive officers for the year ended December 31, 2015, as set forth in this proxy statement.
3. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2016.
4. To transact any other business that may properly come before the 2016 annual meeting.
|
| 2015-06-23 |
股东大会：
将于2015-07-29召开股东大会
会议内容 ▼▲
- 1.To elect two nominees for Class II director named in this proxy statement, each to hold office until our 2018 annual meeting of stockholders or until his successor is duly elected and qualified.
2.To vote, on an advisory basis, to approve the compensation of our named executive officers for the year ended December 31, 2014, as set forth in this proxy statement.
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2015.
4.To transact any other business that may properly come before the 2015 annual meeting.
|
| 2014-04-10 |
股东大会：
将于2014-05-21召开股东大会
会议内容 ▼▲
- 1. elect two nominees for Class I director named in the proxy statement to hold office until our 2017 annual meeting of stockholders or until his successor is duly elected and qualified;
2. vote, on an advisory basis, to approve the compensation of our named executive officers for the year ended December 31, 2013, as set forth in the proxy statement;
3. ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2014.
|
| 2013-04-24 |
股东大会：
将于2013-06-06召开股东大会
会议内容 ▼▲
- 1. To elect two nominees for Class III director named in this proxy statement to hold office until our 2016 annual meeting of stockholders or until his successor is duly elected and qualified;
2. To vote, on an advisory basis, to approve the compensation of our named executive officers for the year ended December 31, 2012, as set forth in this proxy statement;
3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2013;
4. To transact any other business that may properly come before the 2013 annual meeting.
|